Publicatie en nieuws overzicht

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.

Timely detection of oesophageal adenocarcinoma (OAC) and even more so its precursor Barrett’s oesophagus (BO) could contribute to decrease OAC incidence and mortality. An accurate, minimally-invasive screening method for BO for widespread use is currently not available. In a proof-of-principle study in 402 patients, we developed and cross-validated a BO prediction model using volatile organic compounds (VOCs) analysis with an electronic nose device. This electronic nose was able to distinguish between patients with and without BO with good diagnostic accuracy (sensitivity 91% specificity 74%) and seemed to be independent of proton pump inhibitor use, the presence of hiatal hernia, and reflux. This technique may enable an efficient, well-tolerated, and sensitive and specific screening method to select high-risk individuals to undergo upper endoscopy.

Subsidieaanvraag gehonoreerd voor project: Van Ademanalyse-Module naar ZorgOplossing (AMZO) De Aeonose is een elektronische neus, die het mogelijk maakt om diverse ziektebeelden te detecteren door middel van ademanalyse. Deze analysemethode is snel en niet-invasief en daarmee ook patiëntvriendelijk.

This year, the Union World Conference on Lung Health was held in Hyderabad, India. At the TBScience pre-conference, an official event entirely devoted to basic and translational tuberculosis (TB) research, study results were presented on the Aeonose exhaled-breath tests in Cape Town.

The Union World Conference on Lung Health 2019 was held in Hyderabad (India) from October 30 – November 2. Dr. Ruvandhi Nathavitharana (Harvard University) presented results on the Aeonose exhaled-breath TB-study in Lima, suggesting Aeonose may meet WHO triage test criteria to rule out TB (90% sensitivity, 70% specificity) in lower-risk patients admitted with cough or TB risk factors.

Een draagbare elektronische neus die aan de adem van patiënten kan ruiken of zij een bepaalde aandoening hebben. Fictie? Zeker niet. The eNose Company in Zutphen werkt al vijftien jaar aan de ontwikkeling van de aeoNose, ooit ontwikkeld voor de politie voor het opsporen van wietplantages, nu voor het diagnosticeren van diverse ziektebeelden. Met de komst van krachtiger computers en artificial intelligence krijgt het bedrijf de wind in de rug.

At the ERS Conference in Madrid (September 28 – October 2, 2019), Sharina Kort (MST, Enschede, the Netherlands) presented clinical study results on diagnosing lung cancer using the Aeonose.